2. Academic Validation
  3. Structure-Activity Relationship Study of Leucyl-3- epi-deoxynegamycin for Potent Premature Termination Codon Readthrough

Structure-Activity Relationship Study of Leucyl-3- epi-deoxynegamycin for Potent Premature Termination Codon Readthrough

  • ACS Med Chem Lett. 2017 Sep 29;8(10):1060-1065. doi: 10.1021/acsmedchemlett.7b00269.
Akihiro Taguchi 1,  Keisuke Hamada 1,  Masataka Shiozuka 2,  Misaki Kobayashi 1,  Saori Murakami 1,  Kentaro Takayama 1,  Atsuhiko Taniguchi 1,  Takeo Usui 3,  Ryoichi Matsuda 2,  Yoshio Hayashi 1
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
  • 2 Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Tokyo 153-8902, Japan.
  • 3 Faculty of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8572, Japan.
PMID: 29057051 DOI: 10.1021/acsmedchemlett.7b00269
Abstract

(+)-Negamycin, isolated from Streptomyces purpeofuscus, shows antimicrobial activity against Gram-negative bacteria and readthrough activity against nonsense mutations. Previously, we reported that two natural negamycin analogues, 5-deoxy-3-epi-negamycin and its leucine adduct, have more potent readthrough activity in eukaryocytes (COS-7 cells) than negamycin but possess no antimicrobial activity and no in vitro readthrough activity in prokaryotic systems. In the present study, on leucyl-3-epi-deoxynegamycin, a structure-activity relationship study was performed to develop more potent readthrough agents. In a cell-based readthrough assay, the derivative 13b with an o-bromobenzyl ester functions as a prodrug and exhibits a higher readthrough activity against TGA-type PTC than the Aminoglycoside G418. This ester (13b) shows an in vivo readthrough activity with low toxicity, suggesting that it has the potential for treatment of hereditary diseases caused by nonsense mutations.

Keywords

(+)-Negamycin; Duchenne muscular dystrophy; Leucyl-3-epi-deoxynegamycin; Readthrough.

Figures
Products